BARCELONA, Spain — In the phase 2 ARCHER trial, ANX007, a novel C1q inhibitor with neuroprotective properties, showed consistent protection against loss of visual acuity in eyes with geographic atrophy. One-year study results as well as 18-month extension data were presented by Usha Chakravarthy, MD, PhD, at the Euretina congress.
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
The treatment showed stability or improvement in the Diabetic Retinopathy Severity Scale (DRSS) and generally the drug was well tolerated.
Conexiant Vision: Delivering trusted clinical content, deep audience engagement, and educational resources for eye care professionals. Discover more through our magazines, newsletters, and events.
KOLOA, Hawaii — Patients with diabetic retinopathy need special care while pregnant, according to a speaker at Retina 2025. Irena Tsui, MD, said hormonal, metabolic…
The success of Mayo Clinic’s first paired living-donor liver transplantation may pave the way for expanded access and more “timely transplant” for patients in need,…
This cohort study examines additional data for children from the Bifocal Lenses in Nearsighted Kids (BLINK) Study to determine whether axial eye growth increases after…
Andrew G. Lee, MD, and Drew Carey, MD, return for this latest episode of the NeuroOp Guru to discuss whether a dead nerve can swell,…
Updates in new antiplatelet therapies, new patient populations for PCI and AI to guide CAD staging were among the top developments in thrombosis and coronary…
Ophthalmology Times – ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.
Following the switch from multifocal to single-vision contact lenses, axial elongation increased by 0.03 mm/year, and myopia progressed at a rate of −0.17 D annually…
